An independent research funded by Novo Nordisk at the University of Leeds shows a significant weight loss among clinically obese individuals with Ozempic (semaglutide). This drug is similar to the naturally-occurring hormone GLP-1 in the body, which targets the sensory receptors of appetite control mechanism (in the hypothalamus portion of the brain), to reduce the hunger and food craving. Novo Nordisk is the manufacturer of semaglutide under the brand name Ozempic.
A study was conducted with a weekly dose of Ozempic on 28 obese people with a body mass index (BMI) between 30 and 45 kg/m2. At the end of the 12-week study, the study has found an average 24 percent reduction in the daily energy intake of the participants. Ozempic has demonstrated a better appetite regulation. People under this treatment had eaten in small amounts and the preference for foods of high-fat content has been reduced. The participants lost about five kg (11 lbs) of body fat over a period of 12 weeks with Ozempic.
The cost of Ozempic once-weekly treatment for type 2 diabetes is about $676 per prescription. The oral form of the drug is under the development. This drug is going to compete with other GLP-1 drugs (Dulaglutide from Trulicity and Bydureon from AstraZeneca). The FDA has approved Ozempic (semaglutide) from Novo Nordisk on December 5, 2017.
The lead author of the study was Professor John Blundell, Psycho-Biology (Biological Psychology), University of Leeds, United Kingdom. The study was published on May 5, 2017, in the journal Diabetes, Obesity and Metabolism. Title of the article was "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity."
Doctors at the London hospital are studying a radical treatment procedure for patients of type 2 diabetes (T2D) to prevent the further worsening of the blood sugar (glucose) levels, to reduce medical expenses and to reduce the need for medicines (insulin injection and drugs). The first procedure was conducted at the University College Hospital (UCH), Bloomsbury, London, United Kingdom.
This procedure was not intended to cure (or prevent) type 2 diabetes (T2D). This procedure takes less than 60 minutes. This procedure involves a brief insertion of a tiny hot water bottle into the upper intestine via the mouth, stomach and duodenum. The tissue lining the duodenum is removed with the hot water balloon (90°C) causing the release of insulin to control blood sugar levels.
Patients of Polycystic Ovary Syndrome (PCOS) or Non-Alcohol Related Fatty Liver Disease (NAFLD) may also be benefited from this treatment. Dr. Rehan Haidry, a gastroenterologist, is leading a team of doctors in conducting the trials at the University College Hospital (UCH), Bloomsbury, London, United Kingdom. Contact cormac[dot]magee[at]nhs[dot]net to participate in the trial.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.